The funding will enable further development of EpiEndo’s lead asset glasmacinal (EP395), the company states. It is the first in a new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, and shows promise as a therapeutic for chronic respiratory diseases, such as COPD.

The data from EpiEndo’s Phase 2a trial of glasmacinal in COPD patients demonstrated that it was well tolerated and reduced neutrophilic inflammation as well as having no detectable impact on the lung microbiome, supporting its claim of negligible anti-microbial activity, the company describes.

The company aims to continue development of glasmacinal in a larger Phase 2b trial. In preparation, key chemical, manufacturing and control (CMC) work is required which this bond issuance will finance.

Related article

A Nordic star on a global mission

EpiEndo Pharmaceuticals is on the rise. The company has recently secured next phase financing and been awarded several prestigious awards, and is on course to potentially change the treatment paradigm for chronic obstructive pulmonary disease. At the Swedish-American Life Science Summit (SALSS) 2021, the Icelandic clinical stage pharma company EpiEndo received the SALSS Rising Star […]


“This funding enables the continued development of glasmacinal, as we deliver the key CMC preparation work needed ahead of a larger future Phase 2 exacerbation reduction trial in COPD patients. With the level of understanding we now have about glasmacinal’s anti-inflammatory and host-defence enhancing properties, we believe that it has real potential as a chronic treatment for patients with COPD who continue to experience exacerbations, despite receiving the current standard of care,” says Maria Bech, CEO of EpiEndo Pharmaceuticals.